Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study

INTRODUCTION: The phosphatidylinositol 3-kinase (PI3K) pathway promotes tumor growth and treatment resistance in non-small cell lung cancer (NSCLC). The aim of the open-label, two-stage, Phase II study BASALT-1 (NCT01820325) was to investigate the pan-PI3K inhibitor buparlisib (BKM120) in patients w...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Thorac Oncol
Main Authors: Vansteenkiste, Johan F., Canon, Jean-Luc, De Braud, Filippo, Grossi, Francesco, De Pas, Tommaso, Gray, Jhanelle E., Su, Wu-Chou, Felip, Enriqueta, Yoshioka, Hiroshige, Gridelli, Cesare, Dy, Grace K., Thongprasert, Sumitra, Reck, Martin, Aimone, Paola, Vidam, Gena Atalla, Roussou, Pantelia, Wang, Ying A., Tomaso, Emmanuelle Di, Soria, Jean-Charles
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4646607/
https://ncbi.nlm.nih.gov/pubmed/26098748
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0000000000000607
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados